Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that ...
Boehringer Ingelheim spent the weekend pointing to survodutide's “targeted” weight loss, but the latest data couldn’t shake off concerns about the obesity drug’s tolerability. The deep dive into ...
In new data from the midphase ZUPREME-1 trial presented Friday, Zealand provided a closer look at the trial win it first ...
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it ...
On Thursday, the public had the first chance to air their grievances about the FDA’s controversial Commissioner’s National ...
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that ...
Affibody may not have expected to be working on izokibep again, but the Swedish biotech hasn’t wasted an opportunity to ...
The structural advantages that allow China to conduct clinical trials more quickly and at lower costs should be leveraged to ...
Even as Zepbound and Mounjaro fire on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes ...
NewLimit’s lead liver combo has proven its worth in preclinical models, Kimmel told Fierce, with the ability to boost ...
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a ...
A first-in-class bispecific antibody-drug conjugate that Bristol Myers Squibb paid $800 million for has shown strong phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results